AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03183128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline(0.9%).
Study NCT00266058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine
Description: participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
Study NCT04217564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counselling
Description: Nutritional counselling based on the nutritional assessment will be conducted. A booklet that contains the whole instructions and dietary records will be provided to help remembering information and record their application of the plan.
Study NCT04747015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby according to the WHO recommendation
Study NCT04747015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation then controlled cord traction (CCT)to the umbilical cord while applying simultaneous counter-pressure to the uterus, through the abdomen(Brandt Andrews maneuver)
Study NCT03361683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
Study NCT03361683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask
Description: Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
Study NCT01821976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ertl Procedure
Study NCT01821976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burgess Procedure
Study NCT00637702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: single dose and multiple dose, escalating
Study NCT03571880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex-assisted isometric strength testing
Description: The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
Study NCT03571880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biodex-assisted isometric strength testing
Description: The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
Study NCT02589223 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory Stimulation
Description: Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
Study NCT02589223 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
Study NCT00554281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of glucose sensor (Paradigm Guardian)
Description: Use glucose sensor to prevent episodes of severe hypoglycemia
Study NCT04747015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cervical traction
Description: sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds. The traction should be adequate to allow the cervix to reach the vaginal introitus. Meanwhile (CCT ) is avoided and watchful waiting for signs of placental separartion till 90 seconds end
Study NCT00760110 — intervention group
Intervention type: DEVICE
Intervention: blood pressure measurements based on HBP or CBP
Description: To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
Study NCT03850197 — intervention group
Intervention type: DEVICE
Intervention: EarPopper
Description: The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150).
Study NCT03850197 — intervention group
Intervention type: DEVICE
Intervention: Tympanometry
Description: The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.
Study NCT03850197 — intervention group
Intervention type: DEVICE
Intervention: Tubomanometry
Description: Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150).
Study NCT01488786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort Vision Device
Description: 2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
Study NCT02373098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: 66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
Study NCT02704182 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
Study NCT02704182 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
Study NCT01974141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone Gel
Description: Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study NCT01974141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapsone Gel Vehicle
Description: Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
Study NCT03681444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: Patients will be provided with any type of food preferred at any time in any quantity
Study NCT03681444 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Clear fluid diet
Description: Patients will be provided with~* Plain water~* Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~* Soup broth (bouillon or consommé)~* Clear sodas, such as ginger ale and Sprite~* Gelatin (Jell-O)~* Tea or coffee with no cream or milk added~* Sports drinks that don't have color
Study NCT03681444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low residue diet
Description: The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list.
Study NCT01988974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert for Atrial Fibrillation Program
Description: Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
Study NCT01988974 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Sleep
Description: Participants will receive a 45 minute face to face instruction about sleep hygiene
Study NCT03681444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
Study NCT03681444 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
Study NCT05904444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microperimetric biofeedback training
Description: Microperimetry biofeedback training is a noninvasive stragegy to develop a new trained retinal locus or strength the spontaneous preferred retinal locus to get better visual performances.The rationale of MBFT consists in reeducating visual system to a new visual condition, promoting retina-brain transmission, and further enhancing synaptic plasticity and neural capacity by acoustic biofeedback or structured light stimulus biofeedback.
Study NCT00473486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed, carboplatin, sorafenib
Description: Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1
Study NCT00473486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed, carboplatin, placebo
Description: Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
Study NCT03382509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BI 1467335
Description: Once Daily
Study NCT03382509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Twice Daily
Study NCT03143803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal capsule coccinia, bougainvillea, catharanthus
Description: A unique combination of 3 herbs that lower blood sugars
Study NCT03143803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking inactive powder
Study NCT05206448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole tablet
Study NCT05206448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole tablet
Study NCT05206448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate
Description: Clomiphene Citrate tablet
Study NCT00603135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line i/v-levetiracetam
Description: No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
Study NCT01348802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Push + Pull
Description: Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
Study NCT01348802 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pull
Description: Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
Study NCT02557061 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal surgery (resection)
Description: Colorectal surgery (resection) is done for patient with colorectal cancer
Study NCT02557061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Pre-operative blood sampling is done for patient with colorectal cancer
Study NCT01986556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 1)
Study NCT02500004 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.
Study NCT02874586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasma exchange combination of immunosuppressive regimens
Study NCT02008565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
Study NCT02008565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
Study NCT02500004 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.
Study NCT01986556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 2, Lot A)
Study NCT02500004 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.
Study NCT02008565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anal exercises with biofeedback
Description: Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
Study NCT02008565 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Anal exercises with biofeedback
Description: Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
Study NCT02008565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
Study NCT02008565 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
Study NCT04414605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)
Description: Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.
Study NCT04414605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Auto-Injector [Cosentyx]
Description: Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
Study NCT02499718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP mode
Description: Noninvasive ventilator
Study NCT02500004 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.
Study NCT04773886 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
Study NCT02500004 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Study NCT02500004 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Study NCT02904837 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Study NCT02904837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.